Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $9.25 Analyst target: $15.50 Upside: 67.57%
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
See the full interactive analysis & chart →Informational only — not investment advice.